FGFR1 and lung cancer: Our present study have found that human lung cancer cells in which brachyury is upregulated are more sensitive to inhibitors PD 173074 or PD 184352 targeting FGFR1/MAPK pathway, whereas FGF/FGFR1 activation-promoted lung cancer cell growth and invasion is potentially abrogated by inhibition of MAPK and brachyury, respectively (Figure 5).